{"id":53387,"date":"2020-06-16T23:26:13","date_gmt":"2020-06-17T06:26:13","guid":{"rendered":"https:\/\/drduru.com\/onetwentytwo\/?p=53387"},"modified":"2020-06-16T23:26:15","modified_gmt":"2020-06-17T06:26:15","slug":"soliton-what-awaits-stock-after-news-on-cellulite-trial","status":"publish","type":"post","link":"https:\/\/drduru.com\/onetwentytwo\/2020\/06\/16\/soliton-what-awaits-stock-after-news-on-cellulite-trial\/","title":{"rendered":"Soliton: What Awaits the Stock After News on Cellulite Trial"},"content":{"rendered":"\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\"><p>&#8220;The Company&#8217;s cash, cash equivalents and restricted cash on hand is sufficient to fund the Company&#8217;s operations into December 2020 but not beyond.&#8221;<\/p><\/blockquote>\n\n\n\n<p>This quote from <a rel=\"noreferrer noopener\" href=\"https:\/\/ir.soliton.com\/press-releases\/detail\/95\/soliton-reports-first-quarter-2020-results\" target=\"_blank\">the May 14 earnings report<\/a> from Soliton (SOLY) is tattooed in my mind as I consider the implications of the company&#8217;s recent good news on cellulite treatment. <\/p>\n\n\n\n<br><script async=\"\" src=\"https:\/\/pagead2.googlesyndication.com\/pagead\/js\/adsbygoogle.js\"><\/script>\n<ins class=\"adsbygoogle\" style=\"display:block; text-align:center;\" data-ad-layout=\"in-article\" data-ad-format=\"fluid\" data-ad-client=\"ca-pub-1196033822186410\" data-ad-slot=\"3478942445\"><\/ins>\n<script>\n     (adsbygoogle = window.adsbygoogle || []).push({});\n<\/script><br>\n\n\n\n<p>On June 12th, Soliton <a rel=\"noreferrer noopener\" href=\"https:\/\/ir.soliton.com\/press-releases\/detail\/98\/soliton-reports-positive-pivotal-cellulite-clinical-trial\" target=\"_blank\">announced encouraging results from treating cellulite<\/a> with a single, 20 to 30 minute application of its Rapid Acoustic Pulse (RAP) device. The company already has approval to use this technology for tattoo removal. Some of Soliton&#8217;s accomplishments in its clinical trial on cellulite treatment with 62 subjects were:<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li>Average 32.5% reduction in Cellulite Severity Score: 85% of subjects had scores from 6.7% to 85.7%.<\/li><li>91.9% of subjects agreed or strongly agreed that their cellulite appeared improved (a subjective measure)<\/li><li>Average pain score of 2.4 (10-point scale) (a subjective measure)<\/li><\/ul>\n\n\n\n<p>The procedure requires no anesthesia and subjects in the trial experienced &#8220;no unexpected or serious adverse events.&#8221; Apparently, the majority of existing cellulite treatments require 4 to 6 treatments although the company is not clear whether those treatment levels achieve equivalent results to the single Soliton RAP application. Soliton provides more details of the trial results including a descriptive video at <a rel=\"noreferrer noopener\" href=\"https:\/\/secure.soliton.com\/cellulite\/\" target=\"_blank\">Cellulite Trial Results<\/a>.<\/p>\n\n\n\n<p>The company is counting on the success of this application to cellulite treatment ever since <a rel=\"noreferrer noopener\" href=\"https:\/\/ir.soliton.com\/press-releases\/detail\/92\/soliton-announces-new-launch-plan-of-next-generation\" target=\"_blank\">the COVID-19 pandemic forced the company to change its market strategy<\/a>. On April 1st, Soliton announced that it will combine tattoo removal and cellulite indications in an integrated device with a single market launch plan. The delay pushed out a mid-2020 &#8220;limited launch&#8221; of the tattoo removal application to a &#8220;launch timeline with early indicators of the recovery of the financial and aesthetic markets, with the objective of identifying an appropriate window of opportunity for a successful product debut.&#8221; Time is ticking with cash running out by December, 2020. <\/p>\n\n\n\n<p>Next up, Soliton will soon submit a 510(k) to the FDA for clearance of its RAP technology for cellulite treatments.\u00a0 The company believes &#8220;&#8230;there is a reasonable expectation that the FDA will allow [the company] to utilize this clearance pathway in order to market the product.&#8221; If Soliton does not get this clearance, the company would have to file a De Novo request which will cost an additional 6 to 9 months of filing and reviews. Given Soliton&#8217;s cash situation, the company cannot afford such a delay. <\/p>\n\n\n\n<p>So with no revenues for the foreseeable future, an unsustainable cash burn rate, and regulatory risks, Soliton will likely need to file for a secondary offering of stock. The company burned through $3.3M in the first quarter, a large jump from the $2.4M it spend in Q1 2019. The company has $7.7M in cash left, so it has to significantly reduce its cash burn just to make it through December.<\/p>\n\n\n\n<p>Fortunately for Soliton, the stock has experienced a sizable recovery since the March collapse in the stock market. A secondary should bring in significantly more cash now.<\/p>\n\n\n\n<p>Up until today&#8217;s 8.2% pullback, SOLY nearly doubled off its March lows.<\/p>\n\n\n\n<div class=\"wp-block-image\"><figure class=\"aligncenter size-large\"><a href=\"https:\/\/drduru.com\/onetwentytwo\/wp-content\/uploads\/2020\/06\/200616_SOLY-Soliton.png\"><img loading=\"lazy\" decoding=\"async\" width=\"1200\" height=\"857\" src=\"https:\/\/drduru.com\/onetwentytwo\/wp-content\/uploads\/2020\/06\/200616_SOLY-Soliton.png\" alt=\"Soliton (SOLY) lost 8.2% on a pullback the $15 level, a level which has represented stiff overhead resistance for 11 months.\" class=\"wp-image-53392\" srcset=\"https:\/\/drduru.com\/onetwentytwo\/wp-content\/uploads\/2020\/06\/200616_SOLY-Soliton.png 1200w, https:\/\/drduru.com\/onetwentytwo\/wp-content\/uploads\/2020\/06\/200616_SOLY-Soliton-768x548.png 768w\" sizes=\"auto, (max-width: 1200px) 100vw, 1200px\" \/><\/a><figcaption><em>Soliton (SOLY) lost 8.2% on a pullback the $15 level, a level which has represented stiff overhead resistance for 11 months.<\/em><br><strong>Source: <a rel=\"noreferrer noopener\" href=\"https:\/\/www.tradingview.com\/x\/N23Yxpll\/\" target=\"_blank\">TradingView.com<\/a><\/strong><\/figcaption><\/figure><\/div>\n\n\n\n<p>Just as time is running out on cash, the clock is likely ticking even faster for a secondary stock offering to provide funds for the company to operate past December. The $15 level has provided resistance for 11 months and did so again in the wake of the news on the cellulite trial. Traders sold the news and forward-looking traders are likely exiting the stock ahead of a secondary offering. In other words, Soliton will likely issue a secondary stock offering sooner than later with the growing risks of a sizable cooling from the previous rally.<\/p>\n\n\n\n<p>I first took an interest in SOLY in May of last year in a piece titled &#8220;<a href=\"https:\/\/drduru.com\/onetwentytwo\/2019\/05\/19\/how-to-invest-in-tattoo-removal-soliton\/\">How to Invest in Tattoo Removal: Soliton<\/a>.&#8221; In that piece I basically laid out a &#8220;buy low, sell high&#8221; strategy given the speculative nature of the stock. I failed to buy low for this last cycle as <a href=\"https:\/\/drduru.com\/onetwentytwo\/2020\/03\/22\/t2108-update-200320\/\">I waited for the stock to trade closer to $5<\/a>, and then I failed to chase the stock after it double bottomed around $7. I will continue to watch what unfolds from the sidelines and determine my next entry point depending on how well the market absorbs a secondary offering. I particularly like buying the stock between $10 and $11 where support awaits at 50 and 200-day moving averages (DMAs).<\/p>\n\n\n\n<p>Be careful out there!<\/p>\n\n\n\n<p>Full disclosure: no position<\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>&#8220;The Company&#8217;s cash, cash equivalents and restricted cash on hand is sufficient to fund the Company&#8217;s operations into December 2020 but not beyond.&#8221; This quote from the May 14 earnings report from Soliton (SOLY) is tattooed in my mind as I consider the implications of the company&#8217;s recent good news on cellulite treatment. On June &#8230; <a title=\"Soliton: What Awaits the Stock After News on Cellulite Trial\" class=\"read-more\" href=\"https:\/\/drduru.com\/onetwentytwo\/2020\/06\/16\/soliton-what-awaits-stock-after-news-on-cellulite-trial\/\">Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[220,300],"tags":[2435,2192,2193],"class_list":["post-53387","post","type-post","status-publish","format-standard","hentry","category-earnings","category-health-care","tag-cellulite-removal","tag-soliton","tag-soly"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Soliton: What Awaits the Stock After News on Cellulite Trial - ONE-TWENTY TWO: Trading Financial Markets<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/drduru.com\/onetwentytwo\/2020\/06\/16\/soliton-what-awaits-stock-after-news-on-cellulite-trial\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Soliton: What Awaits the Stock After News on Cellulite Trial - ONE-TWENTY TWO: Trading Financial Markets\" \/>\n<meta property=\"og:description\" content=\"&#8220;The Company&#8217;s cash, cash equivalents and restricted cash on hand is sufficient to fund the Company&#8217;s operations into December 2020 but not beyond.&#8221; This quote from the May 14 earnings report from Soliton (SOLY) is tattooed in my mind as I consider the implications of the company&#8217;s recent good news on cellulite treatment. On June ... Read more\" \/>\n<meta property=\"og:url\" content=\"https:\/\/drduru.com\/onetwentytwo\/2020\/06\/16\/soliton-what-awaits-stock-after-news-on-cellulite-trial\/\" \/>\n<meta property=\"og:site_name\" content=\"ONE-TWENTY TWO: Trading Financial Markets\" \/>\n<meta property=\"article:published_time\" content=\"2020-06-17T06:26:13+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2020-06-17T06:26:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/drduru.com\/onetwentytwo\/wp-content\/uploads\/2020\/06\/200616_SOLY-Soliton.png\" \/>\n<meta name=\"author\" content=\"Dr. Duru\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@drduru\" \/>\n<meta name=\"twitter:site\" content=\"@drduru\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Dr. Duru\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/drduru.com\\\/onetwentytwo\\\/2020\\\/06\\\/16\\\/soliton-what-awaits-stock-after-news-on-cellulite-trial\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/drduru.com\\\/onetwentytwo\\\/2020\\\/06\\\/16\\\/soliton-what-awaits-stock-after-news-on-cellulite-trial\\\/\"},\"author\":{\"name\":\"Dr. Duru\",\"@id\":\"https:\\\/\\\/drduru.com\\\/onetwentytwo\\\/#\\\/schema\\\/person\\\/d9569fde6c701b021a8d958f775be9a0\"},\"headline\":\"Soliton: What Awaits the Stock After News on Cellulite Trial\",\"datePublished\":\"2020-06-17T06:26:13+00:00\",\"dateModified\":\"2020-06-17T06:26:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/drduru.com\\\/onetwentytwo\\\/2020\\\/06\\\/16\\\/soliton-what-awaits-stock-after-news-on-cellulite-trial\\\/\"},\"wordCount\":749,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/drduru.com\\\/onetwentytwo\\\/#\\\/schema\\\/person\\\/d9569fde6c701b021a8d958f775be9a0\"},\"image\":{\"@id\":\"https:\\\/\\\/drduru.com\\\/onetwentytwo\\\/2020\\\/06\\\/16\\\/soliton-what-awaits-stock-after-news-on-cellulite-trial\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/drduru.com\\\/onetwentytwo\\\/wp-content\\\/uploads\\\/2020\\\/06\\\/200616_SOLY-Soliton.png\",\"keywords\":[\"cellulite removal\",\"Soliton\",\"SOLY\"],\"articleSection\":[\"Earnings\",\"Health Care\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/drduru.com\\\/onetwentytwo\\\/2020\\\/06\\\/16\\\/soliton-what-awaits-stock-after-news-on-cellulite-trial\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/drduru.com\\\/onetwentytwo\\\/2020\\\/06\\\/16\\\/soliton-what-awaits-stock-after-news-on-cellulite-trial\\\/\",\"url\":\"https:\\\/\\\/drduru.com\\\/onetwentytwo\\\/2020\\\/06\\\/16\\\/soliton-what-awaits-stock-after-news-on-cellulite-trial\\\/\",\"name\":\"Soliton: What Awaits the Stock After News on Cellulite Trial - ONE-TWENTY TWO: Trading Financial Markets\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/drduru.com\\\/onetwentytwo\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/drduru.com\\\/onetwentytwo\\\/2020\\\/06\\\/16\\\/soliton-what-awaits-stock-after-news-on-cellulite-trial\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/drduru.com\\\/onetwentytwo\\\/2020\\\/06\\\/16\\\/soliton-what-awaits-stock-after-news-on-cellulite-trial\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/drduru.com\\\/onetwentytwo\\\/wp-content\\\/uploads\\\/2020\\\/06\\\/200616_SOLY-Soliton.png\",\"datePublished\":\"2020-06-17T06:26:13+00:00\",\"dateModified\":\"2020-06-17T06:26:15+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/drduru.com\\\/onetwentytwo\\\/2020\\\/06\\\/16\\\/soliton-what-awaits-stock-after-news-on-cellulite-trial\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/drduru.com\\\/onetwentytwo\\\/2020\\\/06\\\/16\\\/soliton-what-awaits-stock-after-news-on-cellulite-trial\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/drduru.com\\\/onetwentytwo\\\/2020\\\/06\\\/16\\\/soliton-what-awaits-stock-after-news-on-cellulite-trial\\\/#primaryimage\",\"url\":\"https:\\\/\\\/drduru.com\\\/onetwentytwo\\\/wp-content\\\/uploads\\\/2020\\\/06\\\/200616_SOLY-Soliton.png\",\"contentUrl\":\"https:\\\/\\\/drduru.com\\\/onetwentytwo\\\/wp-content\\\/uploads\\\/2020\\\/06\\\/200616_SOLY-Soliton.png\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/drduru.com\\\/onetwentytwo\\\/2020\\\/06\\\/16\\\/soliton-what-awaits-stock-after-news-on-cellulite-trial\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/drduru.com\\\/onetwentytwo\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Soliton: What Awaits the Stock After News on Cellulite Trial\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/drduru.com\\\/onetwentytwo\\\/#website\",\"url\":\"https:\\\/\\\/drduru.com\\\/onetwentytwo\\\/\",\"name\":\"ONE-TWENTY TWO: Trading Financial Markets\",\"description\":\"Exploring the poetry in financial markets for students of money and economy since the year 2000.\",\"publisher\":{\"@id\":\"https:\\\/\\\/drduru.com\\\/onetwentytwo\\\/#\\\/schema\\\/person\\\/d9569fde6c701b021a8d958f775be9a0\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/drduru.com\\\/onetwentytwo\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":[\"Person\",\"Organization\"],\"@id\":\"https:\\\/\\\/drduru.com\\\/onetwentytwo\\\/#\\\/schema\\\/person\\\/d9569fde6c701b021a8d958f775be9a0\",\"name\":\"Dr. Duru\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/drduru.com\\\/onetwentytwo\\\/wp-content\\\/uploads\\\/2018\\\/09\\\/cropped-masthead-header.jpg\",\"url\":\"https:\\\/\\\/drduru.com\\\/onetwentytwo\\\/wp-content\\\/uploads\\\/2018\\\/09\\\/cropped-masthead-header.jpg\",\"contentUrl\":\"https:\\\/\\\/drduru.com\\\/onetwentytwo\\\/wp-content\\\/uploads\\\/2018\\\/09\\\/cropped-masthead-header.jpg\",\"width\":900,\"height\":100,\"caption\":\"Dr. Duru\"},\"logo\":{\"@id\":\"https:\\\/\\\/drduru.com\\\/onetwentytwo\\\/wp-content\\\/uploads\\\/2018\\\/09\\\/cropped-masthead-header.jpg\"},\"sameAs\":[\"http:\\\/\\\/www.drduru.com\\\/onetwentytwo\",\"https:\\\/\\\/www.instagram.com\\\/drduru_market_breadth\\\/\",\"https:\\\/\\\/x.com\\\/drduru\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Soliton: What Awaits the Stock After News on Cellulite Trial - ONE-TWENTY TWO: Trading Financial Markets","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/drduru.com\/onetwentytwo\/2020\/06\/16\/soliton-what-awaits-stock-after-news-on-cellulite-trial\/","og_locale":"en_US","og_type":"article","og_title":"Soliton: What Awaits the Stock After News on Cellulite Trial - ONE-TWENTY TWO: Trading Financial Markets","og_description":"&#8220;The Company&#8217;s cash, cash equivalents and restricted cash on hand is sufficient to fund the Company&#8217;s operations into December 2020 but not beyond.&#8221; This quote from the May 14 earnings report from Soliton (SOLY) is tattooed in my mind as I consider the implications of the company&#8217;s recent good news on cellulite treatment. On June ... Read more","og_url":"https:\/\/drduru.com\/onetwentytwo\/2020\/06\/16\/soliton-what-awaits-stock-after-news-on-cellulite-trial\/","og_site_name":"ONE-TWENTY TWO: Trading Financial Markets","article_published_time":"2020-06-17T06:26:13+00:00","article_modified_time":"2020-06-17T06:26:15+00:00","og_image":[{"url":"https:\/\/drduru.com\/onetwentytwo\/wp-content\/uploads\/2020\/06\/200616_SOLY-Soliton.png","type":"","width":"","height":""}],"author":"Dr. Duru","twitter_card":"summary_large_image","twitter_creator":"@drduru","twitter_site":"@drduru","twitter_misc":{"Written by":"Dr. Duru","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/drduru.com\/onetwentytwo\/2020\/06\/16\/soliton-what-awaits-stock-after-news-on-cellulite-trial\/#article","isPartOf":{"@id":"https:\/\/drduru.com\/onetwentytwo\/2020\/06\/16\/soliton-what-awaits-stock-after-news-on-cellulite-trial\/"},"author":{"name":"Dr. Duru","@id":"https:\/\/drduru.com\/onetwentytwo\/#\/schema\/person\/d9569fde6c701b021a8d958f775be9a0"},"headline":"Soliton: What Awaits the Stock After News on Cellulite Trial","datePublished":"2020-06-17T06:26:13+00:00","dateModified":"2020-06-17T06:26:15+00:00","mainEntityOfPage":{"@id":"https:\/\/drduru.com\/onetwentytwo\/2020\/06\/16\/soliton-what-awaits-stock-after-news-on-cellulite-trial\/"},"wordCount":749,"commentCount":0,"publisher":{"@id":"https:\/\/drduru.com\/onetwentytwo\/#\/schema\/person\/d9569fde6c701b021a8d958f775be9a0"},"image":{"@id":"https:\/\/drduru.com\/onetwentytwo\/2020\/06\/16\/soliton-what-awaits-stock-after-news-on-cellulite-trial\/#primaryimage"},"thumbnailUrl":"https:\/\/drduru.com\/onetwentytwo\/wp-content\/uploads\/2020\/06\/200616_SOLY-Soliton.png","keywords":["cellulite removal","Soliton","SOLY"],"articleSection":["Earnings","Health Care"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/drduru.com\/onetwentytwo\/2020\/06\/16\/soliton-what-awaits-stock-after-news-on-cellulite-trial\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/drduru.com\/onetwentytwo\/2020\/06\/16\/soliton-what-awaits-stock-after-news-on-cellulite-trial\/","url":"https:\/\/drduru.com\/onetwentytwo\/2020\/06\/16\/soliton-what-awaits-stock-after-news-on-cellulite-trial\/","name":"Soliton: What Awaits the Stock After News on Cellulite Trial - ONE-TWENTY TWO: Trading Financial Markets","isPartOf":{"@id":"https:\/\/drduru.com\/onetwentytwo\/#website"},"primaryImageOfPage":{"@id":"https:\/\/drduru.com\/onetwentytwo\/2020\/06\/16\/soliton-what-awaits-stock-after-news-on-cellulite-trial\/#primaryimage"},"image":{"@id":"https:\/\/drduru.com\/onetwentytwo\/2020\/06\/16\/soliton-what-awaits-stock-after-news-on-cellulite-trial\/#primaryimage"},"thumbnailUrl":"https:\/\/drduru.com\/onetwentytwo\/wp-content\/uploads\/2020\/06\/200616_SOLY-Soliton.png","datePublished":"2020-06-17T06:26:13+00:00","dateModified":"2020-06-17T06:26:15+00:00","breadcrumb":{"@id":"https:\/\/drduru.com\/onetwentytwo\/2020\/06\/16\/soliton-what-awaits-stock-after-news-on-cellulite-trial\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/drduru.com\/onetwentytwo\/2020\/06\/16\/soliton-what-awaits-stock-after-news-on-cellulite-trial\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/drduru.com\/onetwentytwo\/2020\/06\/16\/soliton-what-awaits-stock-after-news-on-cellulite-trial\/#primaryimage","url":"https:\/\/drduru.com\/onetwentytwo\/wp-content\/uploads\/2020\/06\/200616_SOLY-Soliton.png","contentUrl":"https:\/\/drduru.com\/onetwentytwo\/wp-content\/uploads\/2020\/06\/200616_SOLY-Soliton.png"},{"@type":"BreadcrumbList","@id":"https:\/\/drduru.com\/onetwentytwo\/2020\/06\/16\/soliton-what-awaits-stock-after-news-on-cellulite-trial\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/drduru.com\/onetwentytwo\/"},{"@type":"ListItem","position":2,"name":"Soliton: What Awaits the Stock After News on Cellulite Trial"}]},{"@type":"WebSite","@id":"https:\/\/drduru.com\/onetwentytwo\/#website","url":"https:\/\/drduru.com\/onetwentytwo\/","name":"ONE-TWENTY TWO: Trading Financial Markets","description":"Exploring the poetry in financial markets for students of money and economy since the year 2000.","publisher":{"@id":"https:\/\/drduru.com\/onetwentytwo\/#\/schema\/person\/d9569fde6c701b021a8d958f775be9a0"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/drduru.com\/onetwentytwo\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":["Person","Organization"],"@id":"https:\/\/drduru.com\/onetwentytwo\/#\/schema\/person\/d9569fde6c701b021a8d958f775be9a0","name":"Dr. Duru","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/drduru.com\/onetwentytwo\/wp-content\/uploads\/2018\/09\/cropped-masthead-header.jpg","url":"https:\/\/drduru.com\/onetwentytwo\/wp-content\/uploads\/2018\/09\/cropped-masthead-header.jpg","contentUrl":"https:\/\/drduru.com\/onetwentytwo\/wp-content\/uploads\/2018\/09\/cropped-masthead-header.jpg","width":900,"height":100,"caption":"Dr. Duru"},"logo":{"@id":"https:\/\/drduru.com\/onetwentytwo\/wp-content\/uploads\/2018\/09\/cropped-masthead-header.jpg"},"sameAs":["http:\/\/www.drduru.com\/onetwentytwo","https:\/\/www.instagram.com\/drduru_market_breadth\/","https:\/\/x.com\/drduru"]}]}},"_links":{"self":[{"href":"https:\/\/drduru.com\/onetwentytwo\/wp-json\/wp\/v2\/posts\/53387","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/drduru.com\/onetwentytwo\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/drduru.com\/onetwentytwo\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/drduru.com\/onetwentytwo\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/drduru.com\/onetwentytwo\/wp-json\/wp\/v2\/comments?post=53387"}],"version-history":[{"count":8,"href":"https:\/\/drduru.com\/onetwentytwo\/wp-json\/wp\/v2\/posts\/53387\/revisions"}],"predecessor-version":[{"id":53396,"href":"https:\/\/drduru.com\/onetwentytwo\/wp-json\/wp\/v2\/posts\/53387\/revisions\/53396"}],"wp:attachment":[{"href":"https:\/\/drduru.com\/onetwentytwo\/wp-json\/wp\/v2\/media?parent=53387"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/drduru.com\/onetwentytwo\/wp-json\/wp\/v2\/categories?post=53387"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/drduru.com\/onetwentytwo\/wp-json\/wp\/v2\/tags?post=53387"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}